coming soon…

1. CECOG Fireside Chat

Changing the ES-SCLC paradigm with immuno-oncology Combinations

 

Univ. Prof. Dr. Marko Jakopovic

Thoracic Oncology Unit
Department for Respiratory Diseases
University Hospital Centre Zagreb, Croatia

Univ Prof Dr. Wolfgang Köstler

Department of Medicine I,
Clinical Division of Oncology,
Medical University of Vienna, Austria

2. CECOG Fireside Chat

Patient needs in later lines of mBC (testing, efficacy of current treatment – what do we need)

 

Univ. Prof Dr. Alexandru Eniu

HÔPITAL RIVIERA-CHABLAIS, VAUD-VALAIS
Spécialiste FMH en oncologie médicale
Responsable Breast Unit, Switzerland

Univ Prof Dr. Rupert Bartsch

Department of Medicine I,
Clinical Division of Oncology,
Medical University of Vienna, Austria

3. CECOG Fireside Chat

Targeted treatment options to improve outcomes in EGFRm NSCLC

Univ. Prof. Dr Bojan Zaric

Institute for Pulmonary Diseases of Vojvodina
Faculty of Medicine
University of Novi Sad, Serbia

Univ. Prof Dr. Martin Filipits

Institute of Cancer Research
Department of Medicine I
Medical University of Vienna

4. CECOG Fireside Chat

How new treatments are impacting the work of Multidisciplinary Teams (MTD) (incl guidelines discussion)

Dr. Mila Petrova

MHAT Nadezhda
Sofia, Bulgaria

Univ. Prof. Dr. Christoph Zielinski

CECOG President

5. CECOG Fireside Chat

Clinical implementation of immuno-oncology therapy in unresectable stage III NSCLC

Univ. Prof.Dr. Tanja Cufer

University Clinic Golnik
Medical Faculty Ljubljana
Slovenia

Univ. Prof. Dr. Rafal Dziadziusko

Department of Oncology and Radiotherapy
Medical University of Gdansk

6. CECOG Fireside Chat

Zoom in for HER2+ space: Pharmacology & clinical (efficacy and safety) for trastuzumab deruxtecan Later lines of treatment

Univ. Prof. Dr. Evandro De Azambuja

Institut Jules Bordet
Belgium

Univ. Prof. Dr. Christoph Zielinski

CECOG President

Sponsored by Astra Zeneca